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The Human Interleukin-2 Receptor:
Analysis of Structure and Function
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INTRODUCTION
Specific antigens are capable of activating clonal populations of resting T cells
when presented by macrophages displaying the appropriate major histocompati-
bility antigens. This activation sequence is initiated by antigen binding to specific
receptors present on the surface of resting T cells. Antigen binding, in the presence
of macrophage-derived interleukin-1 (IL-1), then triggers the de novo synthesis
and secretion of interleukin-2 (IL-2 or T-cell growth factor) (Morgan et al, 1976)
and the transient expression of high and low affinity IL-2 receptors (Smith 1980,
Robb 1984, Greene & Robb 1985, Greene et al, 1986), The subsequent interaction
of IL-2 with its high affinity membrane receptor stimulates cellular proliferation,
resulting in an expansion of the antigen-reactive clonal T-cell population. This
activation process ultimately culminates in the generation of specific effector
cells which mediate helper, suppressor, and cytotoxic T-cell functions. The early
increase in IL-2 receptor expression is subsequently followed by a decline in
receptor number which may play an important regulatory role in the termination
of the T-cell immune response. Thus, the specificity, magnitude, and duration of
the T-cell immune response is controlled in part through the transient display of
IL-2 receptors, IL-2 receptor expression may also play an important role in the
nonnal B-cell immune response (Jung et al, 1984, Tsudo et al, 1984, Waldmann
et al, 1984a, Zubler et al, 1984, Nakagawa et al, 1985), Recent studies have
demonstrated that activated B cells express high affinity IL-2 receptors and that
IL-2 promotes augmented proliferation and differentiation of these cells in vitro.
Progress in the biochemical and molecular characterization of the human
IL-2 receptor was facilitated by the identification of monoclonal anti-receptor
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antibodies. The first such antibody in the human system was anti-Tac (Uchiyama
et al. 1981). Utilizing this antibody, the IL-2 receptor has been biochemically
characterized and purified (Leonard et al. 1982, 1983, 1984a, 1985a, Miyawaki
et al. 1982, Depper et al. 1983, Robb & Greene 1983, Wano et al. 1984), cDNAs
for the receptor molecularly cloned (Leonard et al. 1984b, Nikaido et al. 1984,
Cosman et al. 1984), and the IL-2 receptor gene isolated and its organization
and location within the human genome defined (Leonard et al. 1985b, c, Ishida
et al. 1985). In addition, deregulated IL-2 receptor expression in leukemic T cells
infected with the human T lymphotropic virus types I and II (HTLV-I and -II)
has been detected (Gootenberg et al. 1981, Depper et al. 1984a, Waldmann et al.
1984b, Kronke 1985a). Early evidence suggests that these retroviruses contain
similar ?ra«^-activator genes whose protein products induce the coexpression of
the IL-2 and IL-2 receptor genes (Greene et al., 1986b). Thus, subversion of
growth control in the early phase of HTLV-I- and -Il-mediated leukemic trans-
formation may involve IL-2-IL-2 receptor-mediated autocrine T-cell growth.
Salient features of the IL-2 receptor at the protein, mRNA, and gene levels, as
well as abnormalities of receptor expression in HTLV-I-infected leukemic T cells,
will be considered in the following sections.
IDENTIFICATION OF ANTI-IL-2 RECEPTOR MONOCLONAL ANTIBODIES
Drs. Takashi Uchiyama and Thomas Waldmann prepared the anti-Tac mono-
clonal antibody using T cells from the first American patient with HTLV-I-
induced adult T-cell leukemia (ATL) for immunization (Uchiyama et al. 1981).
This antibody reacted with activated but not resting T cells and was therefore
named anti-Tae. Subsequent study of the Tac antigen revealed that it was the
human IL-2 receptor. Evidence supporting this conclusion included the following
findings: (a) anti-Tac blocks IL-2-dependent T-cell proliferation (Leonard et al.
1982); (b) anti-Tac inhibits the binding ofradiolabeled IL-2 (Leonard et al. 1982)
and IL-2 inhibits the binding of radiolabeled anti-Tac (Robb & Greene 1983);
(c) both immobilized IL-2 and anti-Tac bind the identical 55 000 dalton membrane
glycoprotein present on activated T cells (Robb & Greene 1983); and (d) both
anti-Tac and anti-IL-2 antibodies precipitate the same 65-70 000 dalton protein






PMA - phorbol myristate acetate
HTLV - human T lymphotropic virus
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Immunoprecipitations with anti-Tac performed under reducing conditions re-
vealed that the IL-2 receptor was a 50000 dalton glycoprotein on HUT-102B2
cells but a 55000 dalton glycoprotein on normal activated T cells (Leonard 1982,
1983, 1985a, Wano et al. 1984). Under nonreducing conditions, the receptor
migrated with a smaller apparent size, suggesting the presence of intrachain
disulfide bonds. As discussed in a later section, the difference in apparent Mr of
the receptor in these cells is produced by altered post-translational processing
rather than differences in the primary amino acid sequence.
Other monoclonal antibodies reactive with the human IL-2 receptor have also
been identified, including B49.9 (Cotner et al. 1983), 2A3 (Urdal et al. 1984), and
7G7/B6 (Rubin et al. 1985). The first two of these antibodies are similar to
anti-Tac; however, 7G7/B6 identifies a distinct receptor epitope which does not
interfere with IL-2 binding or action. Each of these three monoclonals reacts
with the same 55 000 dalton membrane structure precipitated by anti-Tac.
IL-2 RECEPTOR BIOSYNTHESIS
Pulse-chase radiolabeling studies and analyses employing tunicamyin, endoglyco-
sidase F, and neuraminidase provided considerable insight into the sequential
steps of IL-2 receptor biosynthesis. At early time points in pulse-chase studies
performed in the presence of tunicamycin to inhibit N-linked glycosylation, a
33 000 Mr protein (p33) was immunoprecipitated with anti-Tac (Leonard et al.
1983, 1985a). This protein corresponded to the unmodified IL-2 receptor peptide,
which was approximately 1500 daltons smaller than the primary translation
product (Mr 34 500) generated in a cell-free wheat germ translation system and
immunoprecipitated with an anti-receptor heteroantiserum (Leonard et al.
1984b). These data are compatible with cotranslational cleavage of a signal
peptide from the primary translation product, thus generating the 33 000 M,
protein. As discussed below, a 21-residue signal peptide was subsequently ident-
ified by sequence analysis of a full-length IL-2 receptor cDNA (Leonard et al.
1984b, Nikaido et al. 1984, Cosman et al. 1984). Pulse-chase labeling in the
absence of tunicamycin did not reveal p33 but rather two larger precursor proteins
of Mr 35 000 and 37000 (p35 and p37) (Leonard et al. 1983, 1985a). These data
suggested that p33 was cotranslationally processed by N-linked glycosylation to
these intermediate forms (Leonard et al. 1983, 1985a). This hypothesis was
confirmed in studies employing endoglycosidase F, which cleaves N-linked sugar
moieties, which converted the p35/p37 doublet to p33. During longer periods of
chase, further modifications of p35 and p37 were detected. These proteins were
exported to the Golgi apparatus where 0-linked sugar and sialic acid were added,
producing a saltatory increase in apparent receptor size to an Mr of 55 000. These
Golgi-associated processing events were blocked by addition of the carboxylie
32 GREENE ET AL.
ionophore, monensin, which is known to interfere with protein transport through
and processing within the Golgi apparatus (Leonard et al. 1985a).
In addition to the introduction of N- and O-linked carbohydrate, the IL-2
receptor protein is also post-translationally modified by sulfation (Leonard et al.
1985a). At present, it is unknown whether the sulfate is introduced into carbo-
hydrate (usually N-linked sugar) or protein (occasionally tyrosine residues). How-
ever, after ["S]sulfuric acid labeling and complete hydrolysis of the labeled pro-
tein, all of the radioactivity was precipitable with barium chloride, indicating
that the label was incorporated as sulfate rather than sulfide. The difference in
apparent size of the HUT-102B2 and normal activated T-cell IL-2 receptor
(50000 Mr versus 55 000 Mr) is at least in part related to diminished addition of
sulfate as well as sialic acid to the leukemic receptor protein. The primary
translation products, unmodified peptides and N-glycosylated precursors, are
identical in size in these two cell types. Thus, the size difference is largely generated
during late Golgi or post Golgi processing. Interestingly, both IL-2 and anti-Tac
immobihzed on bead supports react with p33, p35, and p37 precursor forms of
the receptor (Leonard et al. 1985a). Thus, post-translational processing of the
IL-2 receptor is not required for IL-2 binding; however, it is possible that these
processing events may alter the resultant affinity of the receptor for its hgand.
Following post-translational modification, the mature receptor protein (Mr
55000 in normal activated T cells) is displayed on the cell surface. Constitutive
phosphorylation of the receptor protein has also been detected (Shackelford «&
Trowbridge 1984, Leonard et al. 1985a), principally involving serine 247 located
within the intracytoplasmic domain. Thus far, convincing evidence for IL-2-
induced phosphorylation of the receptor has not been obtained; however, this
possibility cannot yet be entirely excluded.
MOLECULAR CLONING OF IL-2 RECEPTOR cDNAs
We approached the problem of isolating IL-2 receptor cDNAs by purifying
receptor protein, determining its N-terminal amino acid sequence, and screening
a cDNA library with synthetic oligonucleotide probes prepared based on the
protein sequence (Leonard et al. 1984b). IL-2 receptor protein was purified from
the HUT-102B2 cell line by immunoaffinity chromatography with anti-Tac. This
cell line was previously demonstrated to express large numbers of IL-2 receptors
(Depper et al. 1984a). The sequence of the N-terminal 29 residues of the protein
was determined by gas phase microsequencing using approximately 200 pmol of
protein per analysis. The sequence obtained was as follows: NH2-glu-leu-cj'5'-a.s/»-
a.y/)-ai/7-/7ro-/7ro-glu-ile-pro-his-ala-thr-phe-lys-ala-met-ala-tyr-lys-glu-gly-thr-met-
leu-asn-cys-glu. Based on residues 3-8 (italicized), a pool of 64 oligonucleotide
probes, 17 bases in length, were synthesized. These probes were radiolabeled with
'̂ P and used to screen a AgtlO cDNA library prepared with HUT-102B2 mRNA.
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Following serial screening, several candidate phage clones were identified, and
three were selected for further study. These cDNAs were subsequently shown to
correspond to the human IL-2 receptor based on selective hybridization of
mRNA, DNA sequence analysis, and expression in COS-1 and L cells (Leonard
et al. 1984b, Greene et al. 1985).
The two longest clones, denoted pIL2R3 (2.4 kb) and pIL2R4 (1.7 kb) (Leon-
ard et al. 1984b), displayed an interesting difference. Clone 3 contained a region
of 216 bases located within the protein coding region which was missing in clone
4. Furthermore, this region was bordered by typical RNA splice donor and
acceptor sites, suggesting that the cDNAs might correspond to an unspliced and
spliced mRNA. In order to determine which of these clones encoded the IL-2
receptor, both ofthe cDNA inserts were expressed in COS-1 cells and these cells
were evaluated for display of membrane IL-2 receptors. Transfection of clone 3,
which retained the 216-base segment, resulted in the production of 50000 M,
receptors which reacted with IL-2 and anti-Tac. In contrast, clone 4 did not direct
the membrane display of IL-2 receptors in these cells. Thus far, the protein
product of clone 4 has not been identified; however, aberrantly spliced mRNA
corresponding to this cDNA has been detected in both normal activated T cells
(Leonard et al. 1985d) and HTLV-I-transformed leukemic T-cell hnes (Kronke
et al. 1985a), indicating that this cDNA does not represent a cloning artifact.
The primary structure of the IL-2 receptor was deduced by sequence analysis
of a full-length IL-2 receptor cDNA (Leonard et al. 1984b). The receptor is
composed of 272 amino acids, including a 21-residue hydrophobic signal peptide.
Thirteen cysteine residues are present, some of which participate in the formation
of intramolecular disulfide bonds. The intergrity of these disulfide bonds is
required for anti-Tac and IL-2 binding. Interchain disulfide bonding has not
been detected. The receptor contains two consensus sequences for N-linked
glycosylation (Asn-X-Ser/Thr) and multiple potential sites for 0-linked sugar
addition. A hydrophobic, presumably transmembrane, domain composed of 19
residues is present near the carboxy terminus of the protein. Given the position
of the signal peptide and N-linked glycosylation sites, the receptor is almost
certainly an NH2 terminus out, COOH terminus in transmembrane structure. An
unexpected feature of the IL-2 receptor is that its intracytoplasmic domain is
composed of only 13 residues. Thus, in contrast to other growth factor receptors,
this intracytoplasmic domain is insufficient in length to encode an enzymatic
activity, in particular, a tyrosine kinase. The intracytoplasmic domain, however,
does contain six positively charged amino acids which may serve to anchor the
receptor protein within the plasma membrane through interactions with the
negatively charged phospholipid headgroups. To test this possibility, we have
introduced a translation termination codon in the cDNA following the fourth
residue of the transmembrane domain. When expressed in mouse fibroblasts, this
truncated "anchor minus" IL-2 receptor cDNA exclusively directs the synthesis
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of a secreted form of the IL-2 receptor which retains the capacity to bind IL-2
and anti-Tac (Treiger et al., 1986).
THE IL-2 RECEPTOR GENE
Utilizing the IL-2 receptor cDNA, phage clones containing the IL-2 receptor
gene were isolated from two genomic libraries. Sequence analysis of these phage
clones demonstrated that the receptor is composed of eight exons and seven
introns and spans a minimum distance of 25 kb (Leonard et al. 1985b). In situ
hybridization studies localized the IL-2 receptor gene to chromosome lOp band
14->15 (Leonard et al. 1985c). To date, karyotypic abnormalities of this region
of chromosome 10 have not been associated with human lymphoid malignancies.
The first exon of the receptor gene encodes the 5' untranslated region as well as
the 21-amino-acid signal peptide required for transport of the protein into the
endoplasmic reticulum. The first intron is quite large, encompassing at least 15
kb. Thus far, phage clones completely bridging the first intron have not been
isolated, hence the precise length of the receptor gene is unknown and may be
considerably greater than the minimal estimate of 25 kb provided. The second
exon encodes the N-terminal 66 amino acids of the mature receptor protein
including one of the two N-glycosylation sites. The third exon contains the next
36 amino acids and the second N-glycosylation site. The fourth exon encodes 72
amino acids which share unexpected homology with the second exon. These data
suggest that these exons were derived from an internal gene duplication event.
Similar homology is present in the mouse IL-2 receptor (Miller et al. 1985),
suggesting that this internal duplication occurred at least 50 million years ago,
prior to the genetic radiation of mouse and man. The location and presence
of these duplicated domains raises the interesting, though presently unproven,
possibility that the IL-2 receptor may contain two ligand-binding sites. The fourth
exon is also homologous to the recognition domain of human complement factor
B (Ba fragment) (Leonard et al. 1985b). The significance of this unexpected
homology is unclear but suggests that exons from these two genes shared an
ancestral relationship. The fourth exon also encodes the 216 bases which are
infrequently removed by aberrant post-transcriptional splicing, resulting in the
joining of exon 3 and exon 5. As noted above, expression of a cDNA correspond-
ing to this aberrantly spliced mRNA, in COS-1 or L cells, does not result in the
display of functional membrane IL-2 receptors (Leonard et al. 1984b). These
data suggest that the fourth exon is either important for effective translation or
transport of the IL-2 receptor or, alternatively, involved in IL-2 and anti-Tac
binding. The sixth exon contains multiple potential sites for 0-linked glycosyla-
tion and, topographically, is located immediately extracytoplasmic to the plasma
membrane. A similarly positioned exon rich in 0-linked glycosylation sites has
been found in the low density lipoprotein receptor (Yamamoto et al. 1984). The
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seventh exon encodes the majority ofthe 19-residue hydrophobic transmembrane
domain, while the eighth exon encodes part of the 13 amino acids comprising
the intracytoplasmic domain as well as the 3' untranslated region of the IL-2
receptor. As discussed below, the 3' untranslated region contains at least three
functional polyadenylation signal sequences as well as the unexpected presence
of multiple Alu repetitive elements located between the second and third poly A
addition sites (Leonard et al. 1985b).
The 5' end of the IL-2 receptor mRNAs may also vary. Primer extension and
SI nuclease protection analyses have demonstrated that activated normal T cells
initiate transcription of receptor mRNA at two discrete sites separated by 58
nucleotides (Leonard et al. 1985b). "TATA-Hke" promotor sequences are present
25-30 bp upstream from each of these initiation sites. This 5' flanking region
contains functional promotor activity, as evidenced by its capacity to direct the
expression of the chloramphenicol-acetyl transferase gene in JURKAT T cells.
Each of the two promotors controlling the two transcription initiation sites
appears to share nearly equivalent strength in normal activated T cells. As
discussed below, a third transcription initiation site has also been identified in
HTLV-I-infected leukemic T cells which display large numbers of IL-2 receptors.
MULTIPLE IL-2 RECEPTOR mRNAs
Northern blotting analysis of activated T-cell RNA revealed three discrete size
classes of IL-2 receptor mRNA (Leonard et al. 1984b). SI nuclease protection
studies indicated that these differently sized mRNAs are produced by the utiliza-
tion of at least three different 3' polyadenylation sequences (Kronke et al. 1985a,
Leonard et al. 1985d). Suboptimal stimulation of normal T cells appears to favor
use of the most distal poly A site, while maximal stimulation produces more
equivalent use of each of the three sites (Kronke et al. 1985a). At present, it is
unknown whether certain receptor mRNA species are more stable or more
efficiently translated than others. The combination of two transcription initiation
sites, the variable post-transcriptional splicing of exon 4, and the three poly A
sites indicates that as many as 12 different IL-2 receptor mRNAs may exist in
activated normal T cells.
IL-2 RECEPTOR EXPRESSION IS TRANSIENT BUT CAN BE REINDUCED
Activation of resting human T cells with phytohemagglutinin (PHA) results in
the induction of IL-2 receptor expression which peaks at 48 to 72 h (Depper et
al. 1984b). This increase in receptor display and the concomitant production of
IL-2 results in T-cell proliferation. However, with longer periods in culture, IL-
2 receptor levels decline and cellular proliferation diminishes (Cantrell & Smith
1983, Depper et al. 1984b). Following 10 to 12 d in culture, 80-90% of the IL-
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2 receptors are lost. The transient nature of IL-2 receptor expression may play
an important role both in the development and in the termination of the T-cell
immune response.
To dissect the regulation of this transient IL-2 receptor expression, peripheral
blood lymphocytes were stimulated with PHA for varying periods of time and
their RNA isolated. These RNAs were then analyzed by Northern blotting
and hybridization with radiolabeled IL-2 receptor cDNA. Mature IL-2 receptor
mRNA was detected within 4 to 8 h after PHA stimulation (Leonard et al.
1985d). A larger RNA species, possibly a nuclear precursor, was produced within
2 h and disappeared as the mature mRNA forms emerged. After peaking at 8 to
24 h, receptor mRNA levels then declined. Nuclear runoff studies indicate that
the rise and fall in whole cell IL-2 receptor mRNA levels reflected, at least in
part, a rise and fall in the transcriptional activity of the IL-2 receptor gene
(Leonard et al. 1985d). Interestingly, whole cell mRNA levels appeared to decline
somewhat earlier than the fall in receptor gene transcription, raising the possibility
that post-transcriptional regulation of IL-2 receptor expression may also occur.
These cultured nonproliferating T cells that have lost the majority of their IL-
2 receptors, however, remain susceptible to signals which stimulate IL-2 receptor
reexpression and a second round of cellular proliferation (Cantrell & Smith 1983,
Depper et al. 1984b, 1985a, Malek & Ashwell 1985, Smith & Cantrell 1985).
Three general types of activation signals capable of inducing IL-2 receptor reex-
pression have been defined. First, reexposure of the cells to mitogenic lectin
(Depper et al 1984b, 1985b) or antigen (Hemler et al. 1984, Kaplan et al. 1984,
Reske-Kunz et al. 1984) produces upregulation of IL-2 receptor expression. For
example, PHA restimulation produces a 2-to-lO-fold increase in receptor number
within 24 h. Actinomycin D and cycloheximide block this mitogen-induced reex-
pression of receptors, suggesting that the response is dependent upon de novo
RNA and protein synthesis. Thus, IL-2 receptor reexpression is not solely me-
diated by the transport of preformed intracellular receptors to the cell surface.
Second, stimulation with the phorbol ester, phorbol myristate acetate (PMA), also
augments IL-2 receptor expression (Depper et al. 1984b, 1985b). Furthermore,
phospholipase C and synthetic congeners of diacylglycerol increase IL-2 receptor
expression. Each of these agents interacts with protein kinase C, suggesting a
possible regulatory role for this enzyme in IL-2 receptor expression. Finally,
addition of IL-2 itself augments IL-2 receptor display (Depper et al. 1985a,
Malek & Ashwell 1985, Smith & Cantrell 1985). IL-2 amplification of IL-2
receptor expression has also been described in freshly isolated, resting T lympho-
cytes (Reem & Yeh 1984, Welte et al. 1984). Similarly, IL-2-induced increases in
IL-2 receptor number have been demonstrated in a cloned B-cell line (5B4) which
constitutively expresses small numbers of IL-2 receptors (Waldmann et al. 1984a).
These effects of IL-2 are produced at ligand concentrations which preferentially
titrate the high, but not low, affinity class of IL-2 receptors (see later section
IL-2 RECEPTOR STRUCTURE AND FUNCTION 37
for discussion of high and low affinity receptors). Low affinity receptors are
preferentially induced in these reexpression experiments; however, the resultant
proliferation suggests that functional high affinity receptors are also induced. It
is possible that high affinity receptor detection is compUcated by the recently
recognized receptor-mediated endocytosis of the high, but not low, affinity class
of receptors (Weissman et al. 1986).
Analyses at the RNA level indicated that PHA, PMA, and IL-2 each aug-
mented IL-2 receptor mRNA production. IL-2-induced increases in receptor gene
transcription were also demonstrated in nuclear runoff assays (Depper et al.
1985a). IL-2 activation of these cells produced concomitant increases in the levels
of c-myc and transferrin receptor mRNAs, but did not alter T-cell antigen (fi-
chain) receptor mRNA levels. The reinduction of IL-2 receptor display by PHA,
PMA, and IL-2 was followed by a decline at 48 to 72 h, indicating that receptor
reexpression is also a transient, nonsustained phenomenon. Despite the ability
of IL-2 to upregulate IL-2 receptor expression in T cells cultured for 10 to 12 d,
this ligand does not block the initial and physiologic decline in receptor levels
occurring after 72 h of activation. This finding may refiect active but transient
repression of IL-2 receptor gene transcription resulting in the initial decline in
receptor number. A similar model of repression has been proposed to explain
the transient expression of the IL-2 gene in activated T cells (Efrat & Kaempfer
1984).
SEQUENTIAL GENE EXPRESSION DURING T-LYMPHOCYTE ACTIVATION
Nuclear transcription studies have also been used to define a temporal sequence
of gene activation in human T cells stimulated with PHA and PMA (Kronke et
al. 1985b). These studies indicated that the proto-oncogene, c-myc, is activated
rapidly reaching peak transcription within 6 to 9 h. These findings are consistent
with the earlier studies of Kelly et al. (1983). c-myc expression is followed by IL-
2 receptor and interferon-gamma transcription which peaks at 9 to 15 h. IL-2
gene transcription is also initiated early but does not reach maximal levels until
24 h. Transcription of these four genes was not inhibited by the addition of
cycloheximide, indicating that gene expression was not dependent upon the
protein products of the other genes. For example, the c-myc protein was not
required for transcription of the IL-2 gene. In contrast, the transferrin receptor
gene was not expressed until 24 h after mitogen activation and did not reach
peak levels until 48 h. Addition of cycloheximide at the initiation of culture
completely blocked transferrin receptor gene transcription, suggesting a depen-
dence on protein synthesis. These results are in agreement with the studies of
Neckers and Cossman who have reported that transferrin receptor expression is
mediated by a prior interaction of IL-2 with its cellular receptor (Neckers &
Cossman 1983).
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IL-2 RECEPTOR EXPRESSION ON ACTIVATED B CELLS
Although early evidence suggested that IL-2 receptor expression was a unique
property of activated T lymphocytes, various lines of evidence have emerged
demonstrating that IL-2 receptors are also present on some activated B cells
(Korsmeyer et al. 1983, Greene et al. 1983, Jung et al. 1984, Tsudo et al. 1984,
Waldmann et al. 1984a, Zubler et al. 1984, Lowenthal et al. 1985, Mittler et al.
1985, Nakagawa et al. 1985). Furthermore, the interaction of IL-2 with these
receptors may play an important role in B-cell growth and differentiation. Low
levels of radiolabeled anti-Tac binding were initially detected on certain Burkitt
B lymphoma cell lines (unpublished observations). Subsequently, Ortega et al.
(1984) demonstrated IL-2 receptors on lipopolysaccharide-stimulated murine B
lymphoblasts. Furthermore, several hairy cell leukemia B-cell tumors (Korsmeyer
et al. 1983, Greene et al. 1983), displaying productive heavy and light chain
immunoglobulin gene rearrangements, were shown to express Tac antigen. Sub-
sequently, several investigators have demonstrated that IL-2 may induce both
proliferation and/or differentiation of normal activated B cells (Jung et al. 1984,
Tsudo et al. 1984, Zubler et al. 1984, Mittler et al. 1985, Nakagawa et al. 1985).
Waldmann et al. (1984a) provided evidence for high affmity IL-2 receptors on a
cloned, activated B-cell line and demonstrated that lL-2 could upregulate the
number of these receptors and augment immunoglobulin production. High affin-
ity IL-2 receptors on B cells were also quantitated by Lowenthal and coworkers
(1985). Despite these findings, the role of IL-2 in in vivo B-cell differentiation
and proliferation remains unresolved; however, in vitro it is now clear that
activated B cells may both display specific high affinity IL-2 receptors and
functionally respond to purified IL-2.
HIGH AND LOW AFFINITY FORMS OF THE IL-2 RECEPTOR
The initial IL-2 receptor binding assays performed by Robb and associates (1981)
with purified radiolabeled IL-2 revealed 2000 to 4000 receptors on the surface of
PHA-activated T lymphoblasts. IL-2 interacted with these sites with unexpectedly
high affinity (Kd of 2 to 10 pM). In contrast, binding studies performed with
radiolabeled anti-Tac antibody suggested 30000 to 60000 IL-2 receptors per
PHA-activated T cell (Depper et al. 1984b). Scatchard analysis of anti-Tac binding
suggested a single affinity class of receptors (Kd 10"' to lO"'" M). This difference
in apparent receptor number was not due to Fc receptor binding by anti-Tac or
secondary to occupancy of potential receptor sites by endogenously produced
IL-2, and there were no apparent errors in the estimation of the specific activities
of the two radiolabeled ligands. These findings suggested the possibility that
different affinity forms of the IL-2 receptor might exist. To examine this hypo-
thesis, the IL-2 binding studies were performed over a much broader range of
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ligand concentrations (Robb et al. 1984). These assays demonstrated a previously
undetected large pool of IL-2 receptors which bound IL-2 with a 1000- to 10000-
fold lower apparent affinity. Similar data supporting high and low affinity forms
of the IL-2 receptor were subsequently provided by Lowenthal and colleagues
(1985); however, these authors found that the affinity difference in the two classes
was less marked (100-fold rather than 1000- to 10000-fold) and proposed that
the conditions of washing might produce this difference. When summed, the
number of high and low affinity IL-2 binding sites approximated the number of
Tac sites within a factor of 2. These data suggest that anti-Tac reacts equivalently
with both the high and low affinity forms of the IL-2 receptor and thus cannot
be used to distinguish these different receptor classes. Interestingly, while the
high affinity receptors represent only 5 to 10% of the total membrane IL-2
receptors, these sites appear to exclusively mediate the growth-promoting re-
sponse to IL-2 (Robb et al. 1981, 1984). The function, if any, of the more
numerous low affinity receptors remains unknown. Weissman and colleagues
(1986) have demonstrated that the high affinity, but not low affinity, IL-2 recep-
tors undergo receptor-mediated endocytosis, further defining a basic functional
difference in these receptor classes.
The structural features which distinguish the high and low affinity IL-2 recep-
tors have not been elucidated; however, three possibilities merit consideration.
First, the high affinity IL-2 receptor could be generated by the assembly of a
receptor complex involving one or more other proteins. This model is particularly
attractive in terms of providing a mechanism for growth signal transduction,
since the intracytoplasmic domain ofthe IL-2 binding protein is only 13 amino
acids in length. It is possible that the other putative protein(s) in the receptor
complex may not only augment receptor affinity but also provide a key com-
ponent(s) involved in signal transmission. A second possibility is that the high
affinity IL-2 receptor is produced by a particular form of post-translational
processing. This model, however, does not address the problems of signal trans-
duction. A third possibility is that the high and low affinity forms of the IL-2
receptor are different proteins encoded by different genes. In this regard, ex-
pression of the human IL-2 receptor cDNA in mouse fibroblasts results in the
expression of only low affinity receptors (Greene et al. 1985). Notwithstanding,
in the human system, both the high and low affinity receptor proteins share
reactivity with anti-Tac; in the mouse system both receptors share epitopes for
two different monoclonal antibodies, 3C7 and 7D4 (Malek et al. 1983). Thus, if
different proteins exist, they must be similar in terms of sharing these monoclonal
binding sites. Recent studies involving expression of human IL-2 receptor cDNA
in mouse T cells have demonstrated that this cDNA is capable of directing the
synthesis of both high and low affinity receptors (Hatakeyama et al. 1985). These
data provide convincing evidence against the two-gene hypothesis for high and
low affinity receptors. The data further indicate that either the necessary com-
40 GREENE ET AL.
panion proteins required for high affinity receptor formation are present in T
lymphocytes but not fibroblasts or, alternatively, that the required post-trans-
lational modification involved in high affinity receptor expression occurs in T
cells but not in fibroblasts.
DEREGULATED IL-2 RECEPTOR EXPRESSION IN HTLV-I-INDUCED T-CELL
LEUKEMIA
HTLV-I is the primary etiologic agent in the adult T-cell leukemia (ATL) (Poicsz
et al. 1980, 1981, Gallo & Wong-Staal 1982, Yoshida et al. 1982). Clinically,
patients with this aggressive and usually fatal leukemia may present with hypercal-
cemia, osteolytic bone lesions, dermal or epidermal tumor infiltrates, and oppor-
tunistic infections (Uchiyama et al. 1977, Bunn et al. 1983). Geographically, ATL
is clustered in areas where HTLV-I is endemic, including the southwestern region
of Japan, the Caribbean basin, the southeastern United States, and sub-Saharan
Africa. Thus far, effective forms of therapy for this leukemia have not been
identified. HTLV-I primarily infects T4+ T cells (helper phenotype); however,
functionally many ATL cell lines display suppressor T-cell activity (Waldmann
et al. 1984b). A uniform finding with cultured ATL cell lines is the expression of
large numbers of IL-2 receptors (Gootenberg et al. 1981, Depper et al. 1984a).
Both high and low affinity receptors are present, and the total receptor number
is usually 5- to 10-fold greater than that present on normal T cells activated with
PHA (30000 to 60000 receptors per cell) (Depper et al. 1984a). The majority of
these long-term ATL cell lines, while displaying IL-2 receptors, neither secrete
IL-2 nor contain detectable amounts of IL-2 mRNA (Arya et al. 1984). Further-
more, many of these cell lines grow in culture independent of exogenous IL-2.
The deregulated expression of IL-2 receptors in these ATL cell lines has been
studied in considerable detail. Receptor display is not the result of chromosomal
translocation, rearrangement, or amplification of the IL-2 receptor gene (Kronke
et al. 1985a). Furthermore, the leukemic and normal IL-2 receptor proteins
appear to share identical amino acid sequences (Leonard et al. 1985b); however,
some size heterogeneity of receptors has been delineated (e.g., HUT-102 cells)
and is produced by differences in post-translational processing. ATL cell lines
constitutively express large quantities of IL-2 receptor mRNA, and each of the
three known poly A addition sites are utilized in a pattern characteristic of
maximally activated T cells (Kronke et al. 1985a). Aberrant post-transcriptional
splicing of exon 4 has been detected in all ATL cell lines studied, as well as in
normal activated T cells. Thus, no evidence has been obtained for dramatic
differences in the post-transcriptional processing of IL-2 receptor mRNA in these
ATL cells. Nuclear transcription assays have confirmed high level IL-2 receptor
gene expression in ATL cells. Paradoxically, the addition of PHA and PMA,
mitogenic agents which activate IL-2 receptor expression in normal T cells.
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produces partial inhibition (60 to 70%) of IL-2 receptor gene transcription in
two different ATL cell hnes (Kronke et al. 1985a). The molecular mechanism of
this inhibition of receptor gene transcription remains undefined at present but
might involve mitogen activation of a repressor system which could also mediate
the physiological decline of IL-2 receptors occurring during the normal T-cell
immune response.
Comparison of the sites of IL-2 receptor transcription initiation in normal and
ATL cells has revealed an interesting difference (Leonard et al. 1985b). As noted
earlier, IL-2 receptor gene transcription in activated normal T cells is initiated at
two principal sites. In contrast, while utilizing these two sites, transcription is
also initiated from a third more 5' site in ATL cells (Leonard et al. 1985b). The
presence of a unique transcription site in these leukemic cells is intriguing in view
of high level receptor expression; however, this site is utilized less frequently than
the two principal sites present in both normal and ATL cells. While it is conceiv-
able that the mRNAs generated from the third transcription initiation site are
more stable or perhaps more efficiently translated, we feel it is unlikely that this
third promotor provides a full explanation for the high level expression of IL-2
receptors encountered in this leukemia.
HTLV-I, while capable of acutely transforming human cord blood T cells,
does not contain a recognized oncogene characteristically present in other acutely
transforming animal retroviruses (Wong-Staal & Gallo 1985). In addition, HTLV-
I does not appear to transform T cells by insertion near an endogenous cellular
oncogene since the sites of proviral integration vary from tumor to tumor (Seiki
et al. 1984). DNA sequence analysis of HTLV-I proviruses has revealed the
expected gag, pol, and em genes in addition to typical retroviral LTR segments.
However, an extra region, termed pX, has also been identified near the 3' end of
the virus (Seiki et al. 1983, 1985, Haseltine et al. 1984, Kiyokawa et al. 1984,
Sodroski et al. 1984, Shimotohno et al. 1985, Wachsman et al. 1985). Sodroski
and colleagues (1984) subsequently demonstrated that an open reading frame
contained within the pX region encoded a protein which was capable of activating
in trans the transcription of genes controlled by the viral LTR. This trans-
activator gene was originally termed LOR or X-LOR but was more recently
renamed tat (/ransactivation of transcription) in view of its apparent function.
Increasing interest has centered on the possibility that the tat protein may not
only augment viral transcription, but also activate the expression of various
cellular genes involved in T-cell transformation. The IL-2 receptor gene represents
one such candidate cellular target for tat activation. To test this possibility, the
tat gene of HTLV-II has been inserted into a retroviral vector (ZIP-NEO), passed
through an amphotropic packaging line (psi AM), and used to infect JURKAT
T cells and RAJI B cells (Greene et al., 1986b). As an additional control, the
/fl/-II gene was also introduced into the ZIP-NEO retrovirus in the anti-sense
orientation. JURKAT T cells producing functional tat-l\ protein were identified
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by their capacity to transactivate the HTLV-I LTR. These cells were then evalu-
ated for changes in IL-2 receptor expression. Northern blot analyses of poly A+
RNA demonstrated the presence of IL-2 receptor mRNA in the JURKAT T cells
containing the ;a/-II gene in the sense orientation (Greene et al., 1986b). In
contrast, IL-2 receptor mRNA was not detectable in the parental JURKAT T
cells, in JURKAT T cells containing the anti-sense tat-ll gene, or in JURKAT
T cells containing the tat-llI gene isolated from the HTLV-III/LAV retrovirus.
In contrast to JURKAT T cells, introduction of the tat-U gene into RAJI B cells
did not produce activation of IL-2 receptor expression.
In addition to IL-2 receptor mRNA, IL-2 receptor protein was also detectable
in the JURKAT-to/-II T cells. Indirect immunofiuorescent studies as well as
immunoprecipitation with anti-Tac demonstrated the presence of the Tac antigen
in the sense but not the anti-sense JURKAT-raJ-II T cells. pH]anti-Tac binding
studies revealed the presence of 1000 to 1500 IL-2 receptor sites in these cells. In
contrast, HUT-102B2 cells, which contain the entire pro virus, display 100-fold
more receptors. This difference in the magnitude of IL-2 receptor expression is
not well understood but may reflect intrinsic properties of the parental JURKAT
T cells used for infection. Alternatively, the ZIP-NEO retrovirus used in these
studies to introduce the tat-ll gene contains a Moloney virus LTR which is not
susceptible to trans-ach\ation by the tat-U protein. Thus, unlike the HTLV-I or -
II provirus where the tat protein trans-activates its own production, tat-ll does
not augment its expression in the ZIP-NEO retroviral vector. Immunoprecipita-
tion studies have confirmed that the JURKAT-fa?-II T cells contain considerably
less tat-ll protein than HTLV-I-infected ATL cell lines. It is possible that high
levels of the tat protein are necessary for full activation of IL-2 receptor ex-
pression.
The to/-II-infected cells were also evaluated for activation of other genes. The
levels of class I major histocompatibility antigen mRNA and actin mRNA were
not significantly changed in these cells. Of interest, the tat-ll protein also induced
IL-2 gene expression in JURKAT T cells but not in RAJI B cells. These findings
raise the intriguing possibility that the tat-ll protein may alter normal growth of
T cells by stimulating autocrine proliferation via the activation of IL-2 and IL-
2 receptor gene expression. However, as noted earlier, the majority of HTLV-I-
infected ATL cell lines, as well as freshly isolated tumor cells from ATL patients,
neither secrete IL-2 nor contain detectable levels of IL-2 mRNA (Arya et al.
1984). Furthermore, the majority of long-term cultured ATL cell lines are not
dependent on IL-2 for growth. These conflicting findings could be explained by
a progression of ATL tumor cells from an early growth factor-dependent stage
to a later growth factor-independent stage. Precedence for such a model exists in
many other tumor systems; however, the event(s) which permits transition from
growth factor dependence to independence is not well understood in these sys-
tems. In ATL cells, this transition would appear to involve persistent high level
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IL-2 receptor display and a loss of IL-2 gene expression which is no longer
required for growth.
The action of the tat gene of HTLV-II may represent a novel retroviral strategy
for perturbing normal growth controls. Retroviruses have now been associated
with the introduction of oncogenes resembling growth factors (v-sis-»platelet-
derived growth factor) or growth factor receptors (v-er6-B^ truncated epidermal
growth factor receptor). In addition, retroviruses may produce leukemic trans-
formation by cw-activation of an endogenous cellular oncogene via promotor-
enhancer insertion (e.g., avian leukosis virus activation of c-myc expression). In
contrast, the HTLV-I and -II retroviruses may employ a third strategy involving
the production of a trans-acting protein which is capable of activating the ex-
pression of the cellular genes encoding a growth factor (IL-2) and its receptor.
As noted earlier, no effective treatment for ATL has been defined. Kronke and
colleagues (1985c) have recently demonstrated that anti-Tac antibody conjugated
to the A chain of ricin toxin is an effective cytotoxic agent in vitro against HTLV-
I-infected T cells. Similarly, FitzGerald et al. (1984) have demonstrated cytotoxic
properties of anti-Tac coupled to Pseudomonas exotoxin for these cells. Though
in vitro results with immunotoxins certainly do not predict in vivo success, clinical
trials of such anti-Tac-toxin conjugates seem appropriate. Presently, anti-Tac-
Pseudomonas exotoxin is being used by Dr. Thomas Waldmann and colleagues
at the National Cancer Institute in an experimental protocol involving ATL
patients.
SUMMARY
Considerable information presently exists regarding the molecular, biochemical,
and biological features of the human IL-2 receptor. The IL-2 receptor protein,
multiple receptor mRNAs, and a single structural gene have now been identified.
The important role of this receptor in normal T-cell growth is well established
and its potential participation in B-cell growth and differentiation appreciated.
The availability of cloned gene products for both the IL-2 receptor and IL-2
may permit the future development of novel biological agents capable of either
augmenting or blunting the T-cell immune response. The intriguing interrelation-
ship of HTLV-I and -II infection and altered IL-2 receptor expression is now
being unraveled. However, the structural difference in high and low affinity
receptors as well as the mechanism by which signals for T-cell growth are
propagated through the high affinity receptor remain dominant, unanswered
questions in the field.
REFERENCES
Arya, S. K., Wong-Staal, F. & Gallo, R. C. (1984) T-cell growth factor gene: lack of
expression in human T cell leukemia lymphoma virus infected cells. Science 223, 1086.
44 GREENE ET AL.
Bunn, P. A., Schechter, G. P., Jaffe, E., Blayney, D., Young, R. C , Matthews, M. J.,
Blattner, W., Broder, S., Robert-Guroff, M. & Gallo, R. C. (1983) Clitiical course of
retrovirus associated adult T cell lymphoma in the United States. N. Engl. J. Med.
309, 257.
Cantrell, D. A. & Smith, K. A. (1983) Transient expression of interleukin 2 receptors.
Consequences for T cell growth. J. Exp. Med. 158, 1895.
Cosman, D., Ceretti, D. P., Larsen, A., Park, L., March, C , Dower, S., Gillis, S. & Urdal,
D. (1984) Cloning, sequence and expression of human interleukin 2 receptor. Nature
321, 768.
Cotner, T., Williams, J. M., Christenson, L., Shapiro, H. M., Strom, T. B. & Strominger,
J. (1983) Simultaneous flow cytometric analysis of human T cell activation antigen
expression and DNA content. J. Exp. Med. 157, 461.
Depper, J. M., Leonard, W. J., Drogula, C , Kronke, M., Waldmann, T. A. & Greene, W.
C. (1985a) Interleukin-2 (IL-2) augments transcription of the interleukin-2 receptor
gene. Proc. Natl. Acad. Sci. USA 82, 4230.
Depper, J. M., Leonard, W J., Kronke, M., Drogula, C, Waldmann, T. A. & Greene, W.
C. (1985b) Activators of protein kinase C and 5-azacytidine induce IL-2 receptor
expression in human T lymphocytes. J. Cell. Biochem. 27, 267.
Depper, J. M., Leonard, W. J., Kronke, M., Noguchi, P. D., Cunningham, R. E., Waldmann,
T. A. & Greene, W. C. (1984b) Regulation of interleukin 2 receptor expression: effects
of phorbol diester, phospholipase C, and reexposure to lectin and antigen. J. Immunol.
133, 3054.
Depper, J. M., Leonard, W. J., Kronke, M., Waldmann, T. A. & Greene, W. C. (1984a)
Augmented T cell growth factor receptor expression in HTLV-1-infected human leuke-
mic T cells. J. Immunol. 133, 1691.
Depper, J. M., Leonard, W. J., Robb, R. J., Waldmann, T. A. & Greene, W. C. (1983)
Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human
lymphocyte activation. J. Immunol. 131, 690.
Efrat, S. & Kaempfer, R. (1984) Control of biologically active interleukin 2 messenger
RNA formation in induced human lymphocytes. Proc. Natl. Acad. Sci. USA 81, 2601.
FitzGerald, D., Waldmann, T. A., Willingham, M. C. & Pastan, I. (1984) Pseudomonas
exotoxin-anti-Tac cell specific immunotoxin, active against cells expressing the T-cell
growth factor receptor. J. Clin. Invest. 74, 966.
Gallo, R. C. & Wong-Staal, R. (1982) Retroviruses as etiologic agents of some animal and
human leukemias and lymphomas and as tools for elucidating the molecular mechan-
ism of leukemogenesis. Blood 60, 545.
Gootenberg, J. E., Ruscetti, F. W., Mier, J. W, Gazdar, A. & Gallo, R. C. (1981) Human
cutaneous T cell lymphoma and leukemic cell lines produce and respond to T cell
growth factor. J. Exp. Med. 154, 1403.
Greene, W. C, Leonard, W. J. & Depper, J. M. (1986) Growth ofhuman T lymphocytes:
an analysis of interleukin-2 and its cellular receptor. In: Progress in Hematology, Vol.
XIV, Brown, E. B., ed., pp. 281-301. Grune & Stratton, Orlando, El.
Greene, W. C, Leonard, W J., Wano, Y., Svethk, P., Peffer, N. J., Sodroski, J. G., Rosen,
C. A. & Haseltine, W. A. (1986b) The transactivator gene ofhuman T lymphotropic
virus type II (HTLV-II) induces interleukin-2 receptor and interleukin-2 cellular gene
expression. Science 232: 877.
Greene, W. C. & Robb, R. J. (1985) Receptors for T-cell growth factor: structure, function
and expression on nonnal and neoplastic cells. In: Contemporary Topics in Molecular
Immunology, Vol. 10, Gillis, S. & Inman, F. P., eds., pp. 1-34. Plenum Press, New
York.
Greene, W. C, Robb, R. J., Svetlik, P B., Rusk, C. M. Depper, J. M. & Leonard, W. J.
IL-2 RECEPTOR STRUCTURE AND FUNCTION 45
(1985) Stable expression of cDNA encoding the human interleukin receptor in eukary-
otic cells. J. Exp. Med. 162, 363.
Greene, W. C , Waldmann, T. A., Cossman, J., Hsu, S.-M., Neckers, L. M., Marshall, S.
L., Jensen, J. R, Bakhshi, A., Leonard, W. J., Depper, J. M., Jaffe, E. S. & Korsmeyer,
S. J. (1983) Hairy cell leukemia: a malignant expansion of B cells which express Tac
antigen. In: Normal and Neopiastic Hematopoiesis. Marx, R & Golde, D., eds., pp.
501-511. Alan Liss, New York.
Haseltine, W. A., Sodroski, J., Patarca, R., Briggs, D., Perkins, D. & Wong-Staal, F. (1984)
Structure of the 3' terminal repeat region of type II human T lymphotropic virus:
evidence for a new coding region. Science 225, 419.
Hatakeyama, M., Minamoto, S., Uchiyama, T, Hardy, R. R., Yamada, G. & Taniguchi,
T. (1985) Reconstitution of functional IL-2 receptor for human interleukin-2 in mouse
cells. Nature 318, 467.
Hemler, M. D., Brenner, M. B., McLean, J. M. & Strominger, J. L. (1984) Antigen
stimulation regulates the level of expression of IL-2 receptors on human T cells. Proc.
Nail. Acad. Sci. USA 81, 2172.
Ishida, N., Kanamori, H., Noma, T., Nikaido, T, Sabe, H., Suzuki, N., Shimizu, A. &
Honjo T. (1985) Molecular cloning and structure of the human interleukin-2 gene.
Nucleic Acids Res. 13, 7579.
Jung, L., Hara, T. & Fu, S. M. (1984) Detection and functional studies of p60-65 (Tac
antigen) on activated human B cells. J. Exp. Med. 160, 1597.
Kaplan, D. R., Braciale, U. L. & Braciale, T. J. (1984) Antigen dependent regulation of
interleukin 2 receptor expression on cloned human cytotoxic T lymphocytes. J. Immu-
nol 133, 1966.
Kelly, K., Cochran, B. H., Stiles, C. D. & Leder, R (1983) Cell specific regulation ofthe
c-myc gene by lymphocyte mitogens and platelet derived growth factor. Cell 35, 603.
Kiyokawa, T, Seiki, M., Imagawa, K., Shimizu, F. & Yoshida, M. (1984) Identification of
a protein (p40*) encoded by a unique sequence pX of human T cell leukemia virus
type I. Gann 75, 747.
Korsmeyer, S. J., Greene, W. C, Cossman, J., Hsu, S.-M., Jensen, J. R, Neckers, L. M.,
Marshall, S. L., Bakhshi, A., Depper, J. M., Leonard, W. J., Jaffe, E. S. & Waldmann,
T. A. (1983) Rearrangement and expression of immunoglohulin genes and expression
of Tac antigen in hairy cell leukemia. Proc. Natl. Acad. Sci. USA 80, 4522.
Kronke, M., Depper, J. M., Leonard, W. J., Vitetta, E. S., Waldmann, T. A. & Greene, W.
C. (1985c) Adult T cell leukemia: a potential target for ricin A chain immunotoxins.
Blood 65, 1416.
Kronke, M., Leonard, W. J., Depper, J. M. & Greene, W. C. (1985a) Deregulation of
interleukin receptor gene expression in HTLV-1 induced adult T cell leukemia. Science
228, 1215.
Kronke, M., Leonard, W. J., Depper, J. M. & Greene, W. C. (1985b) Sequential expression
of genes involved in human T lymphocyte growth and differentiation. J. Exp. Med.
161, 1593.
Leonard, W. J., Depper, J. M., Uchiyama, T., Smith, K. A., Waldmann, T. A. & Greene,
W. C. (1982) A monoclonal antibody that appears to recognize the receptor for human
T-cell growth factor; partial characterization of the receptor. Nature 300, 267.
Leonard, W. J., Depper, J. M., Crahtree, G. R., Rudikoff, S., Pumphrey, J., Rohh, R. J.,
Kronke, M., Svetlik, R B., Peffer, N. J., Waldmann, T A. & Greene, W. C. (1984b)
Molecular cloning and expression of cDNAs for the human interleukin-2 receptor.
Nature 311, 626.
Leonard, W. J., Depper, J. M., Kronke, M., Reffer, N. J., Svetlik, R B., Kanehisa, M.,
Sullivan, M. & Greene, W. C. (1985h) Structure of the human interleukin-2 receptor
gene. Science 230, 633.
46 GREENE ET AL.
Leonard, W. J., Depper, J. M., Kronke, M., Robb, R. J., Waldmann, T. A. & Greene, W.
C. (1985a) The human receptor for T-cell growth factor: evidence for variable post
translational processing, phosphorylation, sulfation and the ability of precursor forms
of the receptor to bind T-cell growth factor. J. BioL Chem. 260, 1872.
Leonard, W. J., Depper, J. M., Robb, R. J., Waldmann, T. A. & Greene, W. C. (1983)
Characterization of the human receptor for T cell growth factor. Proc. Natl. Acad.
Sci. USA 80, 6957.
Leonard, W. J., Depper, J. M., Waldmann, T. A. & Greene, W. C. (1984a) A monoclonal
antibody to the human receptor for T cell growth factor. In: Receptors and Recognition,
Vol. 17, Greaves, M., ed., pp. 45-66. Chapman & Hall, London.
Leonard, W. J., Donlan, T. A., Lebo, R. V. & Greene, W. C. (1985c) Localization of the
gene encoding the human interleukin-2 receptor on chromosome 10. Science 228, 1547.
Leonard, W. J., Kronke, M., Peffer, N. J., Depper, J. M. & Greene, W. C. (1985d) Interleukin
2 receptor gene expression in normal human T lymphocytes. Proc. Natl. Acad. Sci.
USA 82, 6281.
Lowenthal, J. W., Zubler, R. H., Nabholz, M. & MacDonald, H. R. (1985) Similarities
between interleukin 2 receptor number and affmity on activated B and T lymphocytes.
Nature 315, 669.
Malek, R. T. & Ashwell, J. D. (1985) Interleukin-2 upregulates expression of its receptor
on a T cell clone. J. Exp. Med. 161, 1575.
Malek, T. R., Robb, R. J. & Shevach, E. M. (1983) Identification and initial characterization
of a rat monoclonal antibody reactive with the murine interleukin 2 receptor ligand
complex. Proc. Natl. Acad. Sci. USA 80, 5694.
Miller, S., Malek, T. R., Leonard, W. J., Greene, W. C , Shevach, E. M. & Germain, J. I.
(1985) Nucleotide sequence and expression of a mouse interleukin 2 receptor cDNA.
J. Immunol. 134, 4212.
Mittler, R., Rao, P., Olini, G., Westberg, E., Newman, W., Hoffman, M. & Goldstein, G.
(1985) Activated human B cells display a functional IL-2 receptor. J. Immunol. 134,
2393.
Miyawaki, T. A., Yachie, A., Uwandana, N., Ohzeki, S., Nagaoki, T. & Taniguchi, N.
(1982) Functional significance of Tac antigen expressed on activated human T lympho-
cytes: Tac antigen interacts with T cell growth factor in cellular proliferation. J.
Immunol. 129, 2474.
Morgan, D. A., Ruscetti, F. W. & Gallo, R. C. (1976) Selective in vitro growth of T
lymphocytes from normal human bone marrows. Science 193, 1007.
Nakagawa, T, Hirano, T, Nakagawa N., Yoshizaki, K. & Kishimoto, T. (1985) Effect of
recombinant IL-2 and gamma-interferon on proliferation and differentiation of human
B cells. J. Immunol. 134, 959.
Neckers, L. M. & Cossman, J. (1983) Transferrin receptor induction in mitogen stimulated
human T lymphocytes is required for DNA synthesis and cell division and is regulated
by interleukin 2. Proc. Natl. Acad. Sci. USA 80, 3494.
Nikaido, T., Shimizu, A., Ishida, N., Sabe, H., Teshigawara, K., Maeda, M., Uchiyama, T,
Yodoi, J. & Honjo, T. (1984) Molecular cloning of cDNA encoding human interleukin 2
receptor. Nature 311, 631.
Ortega-R., G., Robb, R. J., Shevach, E. M. & Malek, T. R. (1984) The murine IL-2
receptor. I. Monoclonal antibodies that define distinct functional epitopes on activated
T cells and react with activated B cells. / . Immunol. 133, 1970.
Poiesz, B. J., Ruscetti, F. W, Gazdar, A. F., Bunn, R A., Minna, J. D. & Gallo, R. C.
(1980) Detection and isolation of type C retrovirus particles from fresh and cultured
lymphocytes of a patient with cutaneous T cell lymphoma. Proc. Natl. Acad. Sci. USA
77, 7415.
IL-2 RECEPTOR STRUCTURE AND FUNCTION 47
Poiesz, B. J., Ruscetti, F. W., Reitz, M. S., Kalyanaraman, V S. & Gallo, R. C. (1981)
Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient
with Sezary T cell leukemia. Nature 294, 268.
Reem, G. & Yeh, N.-H. (1984) Interleukin 2 regulates expression of its receptor and
synthesis of gamma interferon by human T lymphocytes. Science 225, 429.
Reske-Kunz, A. B., von Steldern, D., Rude, E., Osawa, H. & Diamantstein, T. (1984)
Interleukin 2 receptors on an insulin specific T cell line: dynamics of receptor ex-
pression. J. Immunol. 133, 1356.
Robb, R. J. (1984) Interleukin 2: the molecule and its function. Immunol. Today 5, 203.
Robb, R. J. & Greene, W. C. (1983) Direct demonstration of the identity of T cell growth
factor binding protein and the Tac antigen. J. Exp. Med. 158, 1332.
Robb, R. J., Greene, W. C. & Rusk, C. M. (1984) Low and high affinity cellular receptors
for interleukin 2: implications for the level of Tac antigen. J. Exp. Med. 160, 1126.
Robb, R. J., Munck, A, & Smith, K. A. (1981) T-cell growth factors: quantification,
specificity, and biological relevance. J. Exp. Med. 154, 1455.
Rubin, L. A., Kurman, C. L., Biddison, W. E., Goldman, N. D. & Nelson, D. L. (1985) A
monoclonal antibody, 7G7/B6, binds to an epitope on the human IL-2 receptor that
is distinct from that recognized by IL-2 or anti-Tac. Hybridoma 4, 91.
Seiki, M., Eddy, R., Shows, T. & Yoshida, M. (1984) Nonspecific integration of HTLV
provirus genome into adult T-cell leukemia cells. Nature 309, 640.
Seiki, M., Hattori, S., Hirayama, Y. & Yoshida, M. (1983) Human adult T cell leukemia
virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell
DNA. Proc. Natl. Acad. Sci. USA 80, 3618.
Seiki, M., Hikikoshi, A., Taniguchi, T. & Yoshida, M. (1985) Expression of the pX gene
of HTLV-I: general splicing mechanism in the HTLV family. Science 228, 1532.
Shackelford, D. A. & Trowbridge, I. S. (1984) Induction of expression and phosphorylation
of the human interleukin 2 receptor by a phorbol diester. J. Biol. Chem. 259, 11706.
Shimotohno, K., Miwa, M., Slamon, D, Chen, I. S., Hoshino, H., Takano, M., Fujino,
M. & Sugimura, T. (1985) Identification of new gene products encoded from X regions
of human T cell leukemia viruses. Proc. Natl. Acad. Sci. USA 82, 302.
Smith, K. A. (1980) T-cell growth factor. Immunol. Rev. 51, 337.
Smith, K. A. & Cantrell, D. A. (1985) Interleukin-2 regulates its own receptor. Proc. Natl.
Acad. Sci. USA 82, 864.
Sodroski, } . G., Rosen, C. A. & Haseltine, W. A. (1984) Trans-acting transcriptional
activation of the long terminal repeat of human T lymphotropic viruses in infected
cells. Science 225, 381.
Treiger, B. F., Leonard, W. J., Svetlik, R, Rubin, L., Nelson, D. L. & Greene, W. C. A
secreted form of the human inerleukin-2 receptor encoded by an "anchor minus"
cDNA. J. Immunol, (in press).
Tsudo, M., Uchiyama, T. & Uchino, H. (1984) Expression of Tac antigen on activated
normal human B cells. J. Exp. Med. 160, 612.
Uchiyama, T, Broder, S. & Waldmann, T. A. (1981) A monoclonal antibody (anti-Tac)
reactive with activated and functionally mature human T cells. J. Immunol. 126, 1393.
Uchiyama, T, Yodoi, J., Sagawa, K., Takatsuki, K. & Uchino, H. (1977) Adult T cell
leukemia: clinical and hematologic features of 16 cases. Blood 50, 481.
Urdal, D. L., March, C. J., Gillis, S., Larsen, A. & Dower, S. K. (1984) Purification and
chemical characterization of the receptor for interleukin 2 from activated human T
lymphocytes and from a human T-cell lymphoma cell line. Proc. Natl. Acad. Sci. USA
81,6481.
Wachsman, W., Golde, D. W., Temple, P. A., Orr, E. C , Clark, S. C. & Chen, I. S. Y.
(1985) HTLV-X gene product: requirement for the env methionine initiation codon.
Science 228, 1534.
48 GREENE ET AL.
Waldmann, T. A., Goldman, C. K. Robb, R. J., Depper, J. M., Leonard, W. J., Sharrow,
S. 0., Bongiovanni, K. R, Korsmeyer, S. J. & Greene, W. C. (1984a) Expression of
interleukin 2 receptors on activated human B cells. J. Exp. Med. 160, 1450.
Waldmann, T. A., Greene, W. C , Sarins, P. S., Saxinger, C , Blayney, D. W., Blattner, W.
A., Goldman, C. K., Bongiovanni, K., Sharrow, S., Depper, J. M., Leonard, W. J.,
Uchiyama, T. & Gallo, R. C. (1984b) Functional and phenotypic comparison of human
T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell
leukemia/lymphoma virus negative Sezary leukemia. J. Clin. Invest. Ti, 1711.
Wano, Y., Uchiyama, T, Fukui, K., Maeda, M., Uchino, H. & Yodoi, J. (1984) Characteri-
zation of human interleukin 2 receptor (Tac antigen) in normal and leukemic T cells:
coexpression of normal and aberrant receptors in HUT 102 cells. / . Immunol. 132,
3005.
Weissman, A. M., Harford, J. B., Svetlik, P. B., Leonard, W. J., Depper, J. M., Waldmann,
T. A., Greene, W. C. & Klausner, R. D. (1986) Only high affinity receptors for
interleukin-2 mediate intemalization of ligand. Proc. Natl. Acad. Sci. USA (in press).
Welte, K., Andreef, M., Platzer, E., Hollaway, K., Rubin, B., Morre, M. & Mertelsman,
R. (1984) Interleukin 2 regulates the expression of Tac antigen in peripheral blood T
lymphocytes. J. Exp. Med. 160, 1390.
Wong-Staal, F. & Gallo, R. C. (1985) Human T lymphotropic retroviruses. Nature 317,
395.
Yamamoto, T, Davis, C. G., Brown, M. S., Schneider, W. J., Casey, M. L., Goldstein, J.
L. & Russel, D. W. (1984) The human LDL receptor: a cysteine rich protein with
multiple Alu sequences in its mRNA. Ceil 39, 27.
Yoshida, M., Miyoshi, I. & Hinuma, Y. (1982) Isolation and characterization of retrovirus
from cell lines of human adult T cell leukemia and its implication in disease. Proc.
Nati Acad. Sci. USA 78, 6476.
Zubler, R. H., Lowenthal, J. W., Erard, F., Hashimoto, N., Devos, R. & MacDonald, H.
R. (1984) Activated B cells express receptors for and proliferate in response to pure
interleukin-2. J. Exp. Med. 160, 1170.

